Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$7.36	$7.73	$2.74 ▼ $9.01	$1.09B	1.73	1.49 million shs	2.01 million shs
CBMG Cellular Biomedicine Group		$19.68	$11.48 ▼ $19.75	$384.69M	1.35	129,776 shs	8,375 shs
IOVA Iovance Biotherapeutics	$3.33 -7.2%	$3.56	$2.70 ▼ $14.23	$1.09B	1.05	7.63 million shs	10.84 million shs
MESO Mesoblast	$11.94 +4.7%	$12.52	$5.78 ▼ $22.00	$1.52B	3.48	271,198 shs	182,913 shs

10 Stocks Set to Soar in Spring 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	-3.29%	-0.27%	-0.94%	-6.36%	+180.92%
CBMG Cellular Biomedicine Group	0.00%	0.00%	0.00%	0.00%	0.00%
IOVA Iovance Biotherapeutics	+0.84%	+12.54%	+7.81%	-42.19%	-69.52%
MESO Mesoblast	-4.28%	+2.64%	-8.65%	-41.60%	+72.73%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADPT Adaptive Biotechnologies	4.1367 of 5 stars	3.5	2.0	0.0	4.2	3.0	2.5	0.6
CBMG Cellular Biomedicine Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	4.5669 of 5 stars	4.4	3.0	0.0	4.2	2.3	2.5	0.6
MESO Mesoblast	1.9208 of 5 stars	3.5	2.0	0.0	0.0	2.0	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	3.00	Buy	$9.40	27.72% Upside
CBMG Cellular Biomedicine Group	0.00	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	2.89	Moderate Buy	$18.22	447.21% Upside
MESO Mesoblast	3.00	Buy	$18.00	50.75% Upside

Current Analyst Ratings Breakdown

Latest CBMG, MESO, IOVA, and ADPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/17/2025	IOVA Iovance Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $16.00
4/14/2025	IOVA Iovance Biotherapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$22.00 ➝ $5.00
3/31/2025	MESO Mesoblast	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/21/2025	ADPT Adaptive Biotechnologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$8.00 ➝ $9.00
3/4/2025	MESO Mesoblast	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/3/2025	IOVA Iovance Biotherapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $15.00
3/3/2025	IOVA Iovance Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $19.00
3/3/2025	IOVA Iovance Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$34.00 ➝ $30.00
2/28/2025	IOVA Iovance Biotherapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$24.00 ➝ $20.00
2/28/2025	IOVA Iovance Biotherapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$7.50 ➝ $6.00
2/28/2025	IOVA Iovance Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00

(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$178.96M	6.11	N/A	N/A	$1.37 per share	5.37
CBMG Cellular Biomedicine Group	$340K	0.00	N/A	N/A	$2.89 per share	0.00
IOVA Iovance Biotherapeutics	$164.07M	6.65	N/A	N/A	$2.28 per share	1.46
MESO Mesoblast	$5.67M	267.55	N/A	N/A	$4.21 per share	2.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$159.49M	-$1.09	N/A	N/A	N/A	-89.12%	-64.65%	-26.45%	5/1/2025 (Estimated)
CBMG Cellular Biomedicine Group	-$49.98M	N/A	N/A	N/A	N/A	N/A	-144.80%	-61.68%	N/A
IOVA Iovance Biotherapeutics	-$444.04M	-$1.30	N/A	N/A	N/A	-451.25%	-58.43%	-45.48%	5/8/2025 (Estimated)
MESO Mesoblast	-$87.96M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest CBMG, MESO, IOVA, and ADPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	IOVA Iovance Biotherapeutics	-$0.25	N/A	N/A	N/A	$83.40 million	N/A
5/1/2025	Q1 2025	ADPT Adaptive Biotechnologies	-$0.28	-$0.20	+$0.08	-$0.20	$42.13 million	N/A
2/27/2025	Q4 2024	IOVA Iovance Biotherapeutics	-$0.26	-$0.26	N/A	-$0.26	$72.17 million	$73.69 million
2/11/2025	Q4 2024	ADPT Adaptive Biotechnologies	-$0.27	-$0.23	+$0.04	-$0.23	$46.05 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
CBMG Cellular Biomedicine Group	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	N/A	2.89	2.81
CBMG Cellular Biomedicine Group	N/A	0.47	0.47
IOVA Iovance Biotherapeutics	N/A	4.22	3.90
MESO Mesoblast	0.21	1.18	1.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
CBMG Cellular Biomedicine Group	21.98%
IOVA Iovance Biotherapeutics	77.03%
MESO Mesoblast	1.43%

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	6.20%
CBMG Cellular Biomedicine Group	8.50%
IOVA Iovance Biotherapeutics	12.10%
MESO Mesoblast	18.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	148.58 million	138.43 million	Optionable
CBMG Cellular Biomedicine Group	217	19.48 million	N/A	Optionable
IOVA Iovance Biotherapeutics	500	327.88 million	267.90 million	Optionable
MESO Mesoblast	80	127.05 million	103.17 million	Optionable

CBMG, MESO, IOVA, and ADPT Headlines

Recent News About These Companies

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

April 29 at 9:01 PM | globenewswire.com

Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

April 28 at 7:44 PM | globenewswire.com

Mesoblast extends payer coverage for Ryoncil to over 100M U.S. lives

April 17, 2025 | markets.businessinsider.com

Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives

April 16, 2025 | globenewswire.com

Mesoblast (NASDAQ:MESO) Shares Gap Down - Here's Why

April 13, 2025 | marketbeat.com

Mesoblast (NASDAQ:MESO) Shares Gap Up - Still a Buy?

April 10, 2025 | marketbeat.com

Top broker says Mesoblast shares can rocket 100%

April 7, 2025 | msn.com

Cantor Fitzgerald Upgrades Mesoblast (NASDAQ:MESO) to "Strong-Buy"

April 5, 2025 | marketbeat.com

HotCopper Highlights for Week 14 – Mesoblast, Cettire, Neurizon & more!

April 4, 2025 | msn.com

Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin' and Not Subject to U.S. Tariffs

April 3, 2025 | globenewswire.com

FY2025 EPS Estimates for Mesoblast Cut by Cantor Fitzgerald

April 3, 2025 | marketbeat.com

Mesoblast (ASX:MSB) Announces Ryoncil Availability But Sees 15% Price Drop Over Past Week

April 2, 2025 | finance.yahoo.com

Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

April 2, 2025 | globenewswire.com

Mesoblast (NASDAQ:MESO) Shares Gap Down - Time to Sell?

April 2, 2025 | marketbeat.com

Mesoblast (NASDAQ:MESO) Trading 2.9% Higher - Here's What Happened

April 1, 2025 | marketbeat.com

Mesoblast announces it entered into NDRA with CMS DHHS for Ryoncil

March 31, 2025 | markets.businessinsider.com

Mesoblast’s Ryoncil Receives US Medicaid Coverage

March 31, 2025 | sharecafe.com.au

Mesoblast kicks off treatment for first 3 kids with graft-host disease. So why are shares down?

March 31, 2025 | msn.com

First Three Children to Commence Treatment With Ryoncil®

March 30, 2025 | globenewswire.com

Mesoblast Becomes Oversold (MESO)

March 30, 2025 | nasdaq.com

2 ASX 200 biotech stocks announcing big news today

March 28, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBMG, MESO, IOVA, and ADPT Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$7.36 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$7.99 +0.63 (+8.56%)

As of 07:44 PM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Cellular Biomedicine Group NASDAQ:CBMG

Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.

Iovance Biotherapeutics NASDAQ:IOVA

$3.33 -0.26 (-7.24%)

Closing price 04:00 PM Eastern

Extended Trading

$3.34 +0.01 (+0.30%)

As of 07:57 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Mesoblast NASDAQ:MESO

$11.94 +0.54 (+4.74%)

Closing price 04:00 PM Eastern

Extended Trading

$12.30 +0.36 (+2.97%)

As of 07:50 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time